|
|
|
|
Marinus Pharmaceuticals Inc (MRNS) |
|
Price: $8.0000
$0.17 
2.106%
|
| Day's High:
| $8.11
| Week Perf:
| 18.52 %
|
| Day's Low: |
$ 7.55 |
30 Day Perf: |
8.99 % |
| Volume (M): |
752 |
52 Wk High: |
$ 11.15 |
| Volume (M$): |
$ 6,015 |
52 Wk Avg: |
$7.00 |
| Open: |
$7.84 |
52 Wk Low: |
$3.46 |
|
|
| Market Capitalization (Millions $) |
420 |
| Shares
Outstanding (Millions) |
53 |
| Employees |
- |
| Revenues (TTM) (Millions $) |
26 |
| Net Income (TTM) (Millions $) |
-28 |
| Cash Flow (TTM) (Millions $) |
35 |
| Capital Exp. (TTM) (Millions $) |
1 |
Marinus Pharmaceuticals Inc
Company Address: 5 Radnor Corporate Center, Suite 500 Radnor 19087 PA
Company Phone Number: 801-4670 Stock Exchange / Ticker: NASDAQ MRNS
| MRNS is expected to report next financial results on November 06, 2023. |
|
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
|
Ibio Inc
In the aftermath of Ibio Inc's recently released fourth-quarter earnings report, the company appears to be grappling with mounting losses and a steep decline in its share value. The financial results for the quarter ended in 2023 revealed a concerning trend of escalating losses for the biotechnology firm.
Earnings Overview:
During the fourth quarter of the 2023 earnings season, Ibio Inc reported a significant increase in its loss per share compared to the same period in the prior year. The loss per share surged from $-0.10 a year ago to $-0.97, representing a substantial deterioration. Additionally, the company witnessed a sequential increase in losses, reaching $-0.55 per share from the previous financial reporting period.
|
|
Mei Pharma Inc
Date: November 15, 2023
Mei Pharma Inc, a leading pharmaceutical company, has experienced a significant turnaround in their financial performance during the financial fourth quarter of 2023, with a reduction in losses per share and improved earnings per share. However, the company witnessed a sharp decline in revenue compared to the previous year, mainly attributed to slowing demand and other market factors.
During the financial fourth quarter of 2023, Mei Pharma Inc reduced their loss per share from $-0.13 a year ago to $-0.08 per share, indicating a 38.46% improvement. Furthermore, earnings per share showed a significant improvement from $-2.32 per share in the preceding quarter to the current figure. These positive numbers highlight the company's ability to manage their expenses effectively and generate better returns for their shareholders.
|
|
Cannapharmarx Inc
The first quarter of 2023 has shown significant promise for Cannapharmarx Inc, a major player in the pharmaceutical preparations industry. While the company has not revealed any top-line figures yet, industry observers are examining the operating shortfall of $-0.720277 million, shedding light on the positive performance of the firm during this period. By comparing it to previous quarters and assessing other growth indicators, we can anticipate a bullish outlook for Cannapharmarx Inc in the near future.
Reduced Losses and Growing Revenue:
In the first quarter of 2022, Cannapharmarx Inc experienced an operating shortfall of $-0.715558 million. However, with effective cost-cutting measures and revenue growth strategies, the company has managed to improve its financial performance in Q1 2023. The company's losses of $-2.072 million in the first quarter of 2022 have been reduced to $-1.413 million, showcasing a significant improvement in their bottom line. This reduction of losses is indicative of a more efficient and profitable operation.
|
|
Benitec Biopharma Inc
Financial News Report: Benitec Biopharma Inc Reports Loss in Fiscal Year 2023
Benitec Biopharma Inc, a major pharmaceutical preparations company, recently released its financial results for the fiscal interval ending June 30, 2023. The company reported a net loss of $-4.661 million, compared to a deficit of $-5.067 million in the corresponding reporting season a year ago.
In terms of earnings per share (EPS), Benitec Biopharma Inc experienced a decline from $-0.16 per share in the previous reporting season to $-0.17 per share in the current period. However, this is an improvement compared to the earnings of $-0.62 per share a year before the reporting season.
|
|
Kintara Therapeutics Inc
Bearish Outlook for Kintara Therapeutics Inc as Fourth Quarter Earnings Paint a Bleak Picture
The fourth quarter earnings report for Kintara Therapeutics Inc (KTRA) has sent shockwaves through the market as the pharmaceutical preparations sector advisors begin to analyze the data. With an operating profit of $3.349 million, KTRA has failed to disclose its revenue for the April to June 2023 financial reporting period. However, comparisons with the previous year's performance highlight a worrying trend.
In the fourth quarter of 2022, KTRA recorded a significantly higher operating profit of $5.458 million, indicating a sharp decline in operating earnings by -38.64%. This decline is a cause for concern as it reflects a substantial decrease in the company's efficiency and overall financial performance. Furthermore, the management has failed to address the issue of diminishing returns, leading to a net deficit of $-14.66 million and a troubling revenue of $0.00 million in the fiscal period 2023.
|
| Per Share |
Current |
| Earnings (TTM) |
-0.11 $ |
| Revenues (TTM) |
0.49 $
|
| Cash Flow (TTM) |
0.67 $ |
| Cash |
3.34 $
|
| Book Value |
1.09 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-0.11 $
|
| Revenues (TTM) |
0.49 $ |
| Cash Flow (TTM) |
0.67 $ |
| Cash |
3.34 $
|
| Book Value |
1.09 $ |
| Dividend (TTM) |
0 $ |
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2023 CSIMarket, Inc. All rights
reserved. This site uses cookies to make your browsing experince better. By
using this site, you agree to the Terms of Service and Privacy Policy - UPDATED
(Read about our Privacy Policy)
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
